Combination therapy including an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
AssigneeAmgen Inc.
InventorsSean Caenepeel, Jude Canon, Paul Hughes, Jonathan D. Oliner, Richard J. Rickles, Anne Y. Saiki
Life of this patent
Estimating the term…
Abstract
The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
Claims20
A method of treating acute myelogenous leukemia (AML), the method comprising administering to a patient in need thereof a therapeutically effective amount of
- 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid and decitabine.
A method of treating acute myelogenous leukemia (AML), the method comprising administering to a patient in need thereof a therapeutically effective amount of
- 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid and cytarabine.
Dependencies are inferred from the claim text.